Andere Sprachen Foghorn Therapeutics Inc.

Aktien

A2QFQD

US3441741077

FHTX

Realtime-Estimate Cboe BZX Andere Börsenplätze 16:31:48 26.04.2024			% 5 Tage	% 1. Jan.
5.26 ^USD	+0.57%		-1.89%	-19.38%

09.04.	Transcript : Foghorn Therapeutics Inc. - Special Call
07.03.	Foghorn Therapeutics Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Foghorn Therapeutics Names Kristian Humer CFO	16.04.
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer	16.04.
Foghorn Therapeutics Inc. Appoints Kristian Humer as Chief Financial Officer	16.04.
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs	09.04.
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09.04.
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference	05.04.
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting	26.03.
Foghorn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07.03.
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook	07.03.
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook	07.03.
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909	05.03.
Foghorn Therapeutics Inc. to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, Including the Selective Inhibitor of BRM, FHD-909	05.03.
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference	28.02.
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference	28.02.
Eli Lilly : un antitumoral de Foghorn a été sélectionné	08.02.
Foghorn Shares Rally as Eli Lilly Plans Clinical Program With Oncology Product	08.02.
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor	08.02.
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor	08.02.
Foghorn Therapeutics Inc. Appoints Stephen J. Dipalma Interim Chief Financial Officer, Effective January 16, 2024	17.01.
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024	08.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Foghorn Therapeutics Inc.

Aktien

A2QFQD

US3441741077

FHTX

Andere Sprachen

Filter